Flossbach Von Storch AG boosted its position in Stryker Co. (NYSE:SYK) by 11.6% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 159,320 shares of the medical technology company’s stock after purchasing an additional 16,561 shares during the period. Flossbach Von Storch AG’s holdings in Stryker were worth $26,525,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of SYK. ERTS Wealth Advisors LLC purchased a new position in Stryker in the fourth quarter valued at approximately $25,000. WASHINGTON TRUST Co bought a new stake in Stryker during the 1st quarter valued at $28,000. Princeton Global Asset Management LLC bought a new stake in Stryker during the 4th quarter valued at $29,000. Filbrandt Wealth Management LLC bought a new stake in Stryker during the 1st quarter valued at $30,000. Finally, Procyon Private Wealth Partners LLC bought a new stake in Stryker during the 4th quarter valued at $31,000. Institutional investors and hedge funds own 73.07% of the company’s stock.

SYK traded down $0.95 during trading on Friday, reaching $184.14. The stock had a trading volume of 1,659,719 shares, compared to its average volume of 1,767,916. The stock has a market cap of $69.38 billion, a PE ratio of 32.36, a PEG ratio of 3.24 and a beta of 0.85. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.77 and a current ratio of 2.58. Stryker Co. has a one year low of $124.54 and a one year high of $226.30. The business has a 50-day moving average of $180.04 and a 200-day moving average of $195.08.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, April 30th. The medical technology company reported $1.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.69 by $0.15. Stryker had a net margin of 14.47% and a return on equity of 24.90%. The business had revenue of $3.59 billion during the quarter, compared to analyst estimates of $3.45 billion. During the same period in the prior year, the business posted $1.88 earnings per share. The company’s revenue was up 2.0% on a year-over-year basis. Equities research analysts forecast that Stryker Co. will post 6.2 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be given a dividend of $0.575 per share. The ex-dividend date of this dividend is Monday, June 29th. This represents a $2.30 annualized dividend and a yield of 1.25%. Stryker’s payout ratio is 27.85%.

A number of brokerages have issued reports on SYK. Morgan Stanley boosted their target price on shares of Stryker from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Friday, May 1st. Zacks Investment Research cut shares of Stryker from a “hold” rating to a “sell” rating and set a $190.00 target price on the stock. in a report on Monday, May 4th. Raymond James lowered their target price on shares of Stryker from $240.00 to $205.00 and set an “outperform” rating on the stock in a report on Monday, April 13th. Oppenheimer reissued a “hold” rating and set a $200.00 target price on shares of Stryker in a report on Friday, May 1st. Finally, Robert W. Baird upped their price target on shares of Stryker from $242.00 to $248.00 and gave the stock an “outperform” rating in a report on Wednesday, January 29th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $214.23.

In other news, VP Katherine Ann Owen sold 9,149 shares of the stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $186.79, for a total transaction of $1,708,941.71. Following the completion of the sale, the vice president now directly owns 1,085 shares in the company, valued at $202,667.15. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Srikant M. Datar sold 200 shares of the stock in a transaction dated Wednesday, May 6th. The stock was sold at an average price of $186.01, for a total transaction of $37,202.00. Following the sale, the director now owns 17,686 shares of the company’s stock, valued at $3,289,772.86. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 12,670 shares of company stock valued at $2,380,526. Company insiders own 6.80% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Featured Story: Exchange-Traded Funds (ETFs)

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.